Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials

Lebwohl M, Warren RB, Sofen H, Imafuku S, Paul C, Szepietowski JC, Spelman L, Passeron T, Vritzali E, Napoli A, Kisa RM, Buck A, Banerjee S, Thaçi D, Blauvelt A. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials. Br J Dermatol. 2024 Jan 16:ljae014. doi: 10.1093/bjd/ljae014. Epub ahead of print. PMID: 38226713.


Related Posts